Biogen Pharmachem Industries (531752) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
6 Jun, 2025Executive summary
Audited financial results for the year ended March 31, 2025, were approved by the Board on May 23, 2025.
Statutory auditors issued an unmodified opinion on the financial statements.
Financial highlights
Revenue from operations for FY25 was Rs. 238.15 lakhs, up from Rs. 135.23 lakhs in FY24.
Net profit after tax for FY25 stood at Rs. 193.07 lakhs, compared to a loss of Rs. 29.27 lakhs in FY24.
Total comprehensive income for FY25 matched net profit at Rs. 193.07 lakhs.
Earnings per share (EPS) for FY25 was Rs. 0.03, compared to Rs. (0.00) in FY24.
Key financial ratios and metrics
Paid-up equity share capital remained at Rs. 6,526.03 lakhs.
Other equity improved to Rs. 2,666.74 lakhs from Rs. (873.99) lakhs year-over-year.
Total assets increased to Rs. 9,201.77 lakhs as of March 31, 2025, from Rs. 5,682.23 lakhs a year earlier.
Latest events from Biogen Pharmachem Industries
- Quarterly unaudited results approved with no material misstatements found by auditors.531752
Q1 26/27 - Revenue and net profit surged year-over-year, with a strong audit opinion and asset growth.531752Q4 25/26
- Board approved unaudited results for Q3 and nine months ended Dec 2025; no audit issues found.531752Q3 25/26
- Q2 FY26 saw a sharp revenue drop, net loss, and higher equity, with strong cash flows.531752Q2 25/26
- Revenue and net profit rebounded sharply year-over-year, with EPS turning positive.531752Q1 25/26
- Q2 FY25 saw Biogen Pharmachem swing to a net loss with declining income and equity.531752Q2 24/25
- Q1 FY25 revenue turned negative and net loss reached ₹15.83 lakhs, reversing prior gains.531752Q1 24/25
- Q3 FY25 saw a net loss and major board changes at Biogen Pharmachem Industries.531752Q3 24/25